Case Study 1 Sample Clauses

Case Study 1. The purpose of Case study 1 was to evaluate the impact of adherence on lipid panel changes (25% reduction from baseline for LDL, TC, and non-HDL). Adherence to statin medication was based on the medication possession ratio (MPR), the main exposure variable in the multivariate regression model. Lipid panel changes were measured at 12 months after initiation of a statin prescription and included low-density lipoproteins (LDL), non-high-density lipoprotein (non- HDL), and triglycerides (TG). Adherence was the main exposure variable of interest and was categorized into adherent or non- adherent based on an arbitrary MPR threshold level of 0.80. Patients who were at or above the threshold were considered adherent; patients who were below the threshold were considered non- adherent. MPR is a surrogate marker for adherence and does not indicate that the patient ingested the medication; however, several studies have reported that it provides an accurate depiction of patient adherence using pharmacy claims data.63,64 MPR was calculated as the number of days supplied of prescription medication divided by days of observation.63,64 MPR was right-skewed; however it was assumed that this would not violate the assumptions of the multiple logistic regression. The dependent variable was change in lipid panel levels which included LDL, non-HDL, and TG. Although these outcomes were continuous, the study categorized them into achieving a 25% reduction from baseline which is considered a clinically significant change.65,66 This level of reduction has been associated with improved clinical outcomes.
AutoNDA by SimpleDocs
Case Study 1. In Case study 1, there was a moderate amount of missing data that ranged from 16% to 19% for individual variables. In the multivariate models, the initial sample size of 7,739 subjects was reduced to 6,074 (~22% missing) due to missing data. Crude analysis was performed to provide a reference for comparison with the complete-case analysis and multiple imputation method. The conclusions from the complete-case analysis were similar to the crude analysis. Further comparisons between the conclusions of the multiple imputation method and complete-case analysis were also similar controlling for age, BMI, gender, baseline lipid values, comorbid conditions (diabetes, hypertension, congestive heart failure, history of myocardial infarction, angina, vascular disease), statin use, ethnicity, and starting medication count. In all scenarios, there were significant associations between adherence and achieving 25% reduction in lipid panel levels.
Case Study 1. In Case study 1, adherent patients were reported to have a higher odd of achieving 25% or more reduction in lipid panel levels relative to non-adherent patients controlling for potential confounding factors. Xxxxxxxxx, et al.36 reported similar findings in that patients who were adherence (MPR ≥ 0.80) had a significant reduction in LDL and non-HDL level relative to non- adherent patients in a veteran population. The use of multiple imputation did not change the conclusion of the complete-case analysis and crude analysis. However, it increased the sample size of the study and improved precision on the confidence limits when compared to the complete-case analysis. It also provided supporting evidence that the conclusions were appropriate and unaffected by missing data.
Case Study 1. Xxxxx, a 45 year old female, works as a primary school teacher. She has been divorced from her husband for six months, and lives with her three children, aged 5, 7, and 9. She has been dating a man in her neighborhood, and reports him as her only new sex partner. She presents to the health facility today because her husband was recently diagnosed with TB, and she was told to come for HIV testing. Her last HIV test was during ANC, when she was pregnant with her last child. It was negative. She has a history of high blood pressure that is well managed with medication. Her HIV test is positive.

Related to Case Study 1

  • The Study 1The parties must comply with, and conduct the Study in accordance with, the Protocol and any conditions of the Reviewing HREC. In addition the parties must comply with the following, as applicable:

  • Feasibility Study A feasibility study will identify the potential costs, service quality and other benefits which would result from contracting out the work in question. The cost analysis for the feasibility study shall not include the Employer’s indirect overhead costs for existing salaries or wages and benefits for administrative staff or for rent, equipment, utilities, and materials, except to the extent that such costs are attributable solely to performing the services to be contracted out. Upon completion of the feasibility study, the Employer agrees to furnish the Union with a copy if the feasibility study, the bid from the Apparent Successful Bidder and all pertinent information upon which the Employer based its decision to contract out the work including, but not limited to, the total cost savings the Employer anticipates. The Employer shall not go forward with contracting out the work in question if more than sixty percent (60%) of any projected savings resulting from the contracting out are attributable to lower employee wage and benefit costs.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Phase 2 Phase 2 is expected to consist of Member Nodes and a select number of Nodes operated by non-Members. The non-Member Nodes will be required to comply with Node hosting terms as set forth by the Council, which may be amended from time to time (the “General Node Terms”).

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Protocol The attached Protocol shall be an integral part of this Agreement.

  • Synchronization, Commissioning and Commercial Operation 4.1.1 The Power Producer shall give at least fifteen (15) days written notice to the SLDC / ALDC / DISCOM as the case may be, of the date on which it intends to synchronize the Power Project to the Grid System. 4.1.2 Subject to Article 4.1.1, the Power Project may be synchronized by the Power Producer to the Grid System when it meets all the connection conditions prescribed in the Grid Code and otherwise meets all other Indian legal requirements for synchronization to the Grid System. 4.1.3 The synchronization equipment and all necessary arrangements / equipment including Remote Terminal Unit (RTU) for scheduling of power generated from the Project and transmission of data to the concerned authority as per applicable regulation shall be installed by the Power Producer at its generation facility of the Power Project at its own cost. The Power Producer shall synchronize its system with the Grid System only after the approval of GETCO / SLDC / ALDC and GEDA. 4.1.4 The Power Producer shall immediately after each synchronization / tripping of generator, inform the sub-station of the Grid System to which the Power Project is electrically connected in accordance with applicable Grid Code. 4.1.5 The Power Producer shall commission the Project within SCOD. 4.1.6 The Power Producer shall be required to obtain Developer and/ or Transfer Permission, Key Plan drawing etc, if required, from GEDA. In cases of conversion of land from Agricultural to Non-Agriculture, the commissioning shall be taken up by GEDA only upon submission of N.A. permission by the Power Producer. 4.1.7 The Power Producer shall be required to follow the Forecasting and Scheduling procedures as per the Regulations issued by Hon’ble GERC from time to time. It is to clarify that in terms of GERC (Forecasting, Scheduling, Deviation Settlement and Related Matters of Solar and Wind Generation Sources) Regulations, 2019 the procedures for Forecasting, Scheduling & Deviation Settlment are applicable to all solar generators having combined installed capacity above 1 MW connected to the State Grid / Substation including those connected via pooling stations.

  • Trials The Ship shall run the following test and trials: (1) Harbour Acceptance Tests, including setting to work of the various equipment;

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!